June 2013
Volume 54, Issue 15
Free
ARVO Annual Meeting Abstract  |   June 2013
Preferential Hyperacuity Perimetry Monitoring in Patients During Treatment of Neovascular Age-related Macular Degeneration
Author Affiliations & Notes
  • Merina Thomas
    Department of Ophthalmology, Retina Division, Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD
    Department of Ophthalmology, University of Illinois at Chicago, Chicago, IL
  • Yulia Wolfson
    Department of Ophthalmology, Retina Division, Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD
  • Voraporn Chaikitmongkol
    Department of Ophthalmology, Retina Division, Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD
    Department of Ophthalmology, Chiang Mai University, Chiang Mai, Thailand
  • Neil Bressler
    Department of Ophthalmology, Retina Division, Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD
  • Footnotes
    Commercial Relationships Merina Thomas, None; Yulia Wolfson, None; Voraporn Chaikitmongkol, None; Neil Bressler, Abbott Medical Optics, inc (F), Alimera Sciences (F), Allergan (F), Bausch &Lomb, Inc (F), Bayer (F), Carl Zeiss Meditec, Inc (F), ForSight Labs, LLC (F), Genentech, Inc (F), Genzyme Corporation (F), Lumenis, Inc (F), Notal VIsion (F), Novartis Pharma AG (F), Pfizer, Inc (F), Regeneron Pharmaceuticals, Inc (F), Roche (F), Thrombogencis (F)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 4173. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Merina Thomas, Yulia Wolfson, Voraporn Chaikitmongkol, Neil Bressler; Preferential Hyperacuity Perimetry Monitoring in Patients During Treatment of Neovascular Age-related Macular Degeneration. Invest. Ophthalmol. Vis. Sci. 2013;54(15):4173. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: To determine how often the home device preferential hyperacuity perimeter (PHP) detects changes in participants being treated with anti-angiogenic therapy for neovascular age-related macular degeneration (AMD), and how often those changes correspond to images of neovascular AMD obtained as part of standard care.

Methods: Patients with neovascular AMD requiring anti-VEGF treatment at a current visit were enrolled into a prospective longitudinal study to investigate the correlation between PHP test scores, quantitative measurements including the rate of normal and abnormal responses, the average size of the presented distortion, and maps of spatial representation of hyperacuity visual field defects to clinical findings including visual acuity and OCT data. Follow-up was at 4 weeks; if treated at 4 weeks, follow-up at 8 weeks also was obtained. An additional PHP test also was administered 1 week following each clinical examination.

Results: 90% (n = 19) of the study candidates had a reliable qualification test score and were followed. 76% (n = 16) of participants were women. The mean age of participants was 77 years, (range 61 to 89 years). Mean visual acuity of the qualification eye was logMAR 0.25 (20/32-20/40). 57% (n = 12) of patients used bifocal eyeglasses during testing. The mean PHP test score improved (decrease in raw score) from baseline to week 1 (-0.10, P = 0.03) and deteriorated (increase in raw score) from baseline to week 4 (+0.09, P = 0.09). For patients who received injections in two subsequent months, the PHP test score improved (decrease in raw score) from week 4 to week 5 (-0.14, P = 0.13) and deteriorated (increase in raw score) to near baseline at week 8 (-0.12, P = 0.12). The mean visual acuity increased slightly (mean difference logMAR +0.06 or 3 letters, P = 0.27) over the 2 month follow-up period. The OCT CST decreased (-1.78 µ, P = 0.46) and the OCT volume increased (0.93 mm3, P = 0.02) over 2 months.

Conclusions: These data suggest that the PHP home device can detect changes during antiangiogenic therapy consistent with the course of the disease as determined by clinical and imaging findings. Further studies would be needed to determine if this device has a role in monitoring patients receiving anti-VEGF therapy in an as needed regimen.

Keywords: 412 age-related macular degeneration • 453 choroid: neovascularization  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×